back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-05-19 17:47 Tx date 2025-05-19 |
$FRX
Fennec Pharmaceuticals Inc. |
Hackman, Jeffrey
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$104,700
+15,000 vol $6.98 each |
15,000 | |
| Filed 2025-05-19 17:46 Tx date 2024-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Hackman, Jeffrey
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-04-03 12:24 Tx date 2025-03-31 |
$FRX
Fennec Pharmaceuticals Inc. |
Hackman, Jeffrey
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$325,000
+50,000 vol $6.50 each |
450,000 | |
| Filed 2024-08-16 12:05 Tx date 2024-08-15 |
$FRX
Fennec Pharmaceuticals Inc. |
Hackman, Jeffrey
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$2,232,000
+400,000 vol $5.58 each |
400,000 | |
| Filed 2024-08-16 12:03 Tx date 2024-08-13 |
$FRX
Fennec Pharmaceuticals Inc. |
Hackman, Jeffrey
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-28,840.8679
-32,149 vol $0.90 each |
||
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$28,840
+32,149 vol $0.90 each |
||
| Filed 2018-11-05 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$97,933
+109,167 vol $0.90 each |
109,167 | |
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$28,840
+32,149 vol $0.90 each |
||
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-28,840.8679
-32,149 vol $0.90 each |
77,018 | |
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-28,840.8679
-32,149 vol $0.90 each |
||
| Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-97,933.7157
-109,167 vol $0.90 each |
33,333 | |
| Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+92,500 vol |
142,500 | |
| Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+50,000 vol |
50,000 | |
| Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+135,000 vol |
135,000 |